Abstract
Background: Apoptosis of brain cells (neurons and glia) has a crucial role in humans' pathology
of traumatic brain injury (TBI). So, a decrease in the apoptosis rate can potentially reduce the harmful
effects and lead to better functional outcomes. Drug repurposing by computational methodologies like
protein-ligand docking allows us to make drug discovery more efficient and less expensive.
Objective: In the current study, we used the methodology to study the inhibitory effect of thousands of
FDA/non-FDA approved, investigational compounds on caspase 3 as one of the most important members
of the cell apoptosis pathway.
Methods: Molecular docking and pharmacokinetic properties calculations were done. The molecular dynamics
(MD) simulations of all complexes and free caspase 3 were carried out. We carried out docking
experiments using in silico methods and docked a pool of medications to the active site of the human
caspase-3 X-ray structure. The best compounds were selected and subjected to pharmacokinetic analysis,
molecular simulation, and free energy calculations.
Results: Finally, 6 components (Naldemedine, Celastrol, Nilotinib, Drospirenone, Lumacaftor, and R-
343) were selected as the best in terms of structural and pharmaceutical properties, low toxicity that can
be administered orally for the preclinical and clinical future investigations.
Keywords:
Caspase 3, apoptosis, virtual screening, docking, MD simulation, MM/PBSA binding free energy.
Graphical Abstract
[3]
Cavallucci, V.; D’Amelio, M. Physiological and pathological role of apoptosis. In: Apoptosome; Springer: Dordrecht, 2009; pp. 1-26.
[27]
Flanagan, L.; Meyer, M.; Fay, J.; Curry, S.; Bacon, O.; Duessmann, H. Low levels of Caspase-3 predict favourable response to 5FUbased chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. Cell Death Dis., 2016, 7(2), e2087-e.
[34]
Fang, B. Structural basis of caspase-3 substrate specificity revealed by crystallography. Enzyme Kinetics, and Computational Modeling; Dissertation, Georgia State University, Georgia, 2009.
[41]
Schrodinger, L. The PyMOL molecular graphics system., 2010, Version 1.3r1.
[42]
Dassault Systèmes, B.I.O.V.I.A. Discovery Studio Modeling Environment, Release 2017; Dassault Systèmes: San Diego, 2016.
[47]
Akocak, S.; Taslimi, P.; Lolak, N.; Isik, M.; Durgun, M.; Budak, Y.; Turkes, C.; Gulcin, I.; Beydemir, S. Synthesis, characterization, and inhibition study of novel substituted phenylureido sulfaguanidine derivatives as α-glycosidase and cholinesterase inhibitors. Chem. Biodivers., 2021, 18(4), e2000958.
[49]
Barkhordari, A.; Mahnam, K.; Mirmohammad-Sadeghi, H. Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-α and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis. J. Mol. Model., 2020, 26(9), 1-11.
[50]
Kumari, R.; Kumar, R. Consortium, OSDD Lynn AJJoci, modeling. g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model., 2014, 54(7), 1951-62.